Browsing Tag
Novo Nordisk
98 posts
Scholar Rock keeps apitegromab FDA decision alive as Europe filing is reset
Scholar Rock has removed Catalent Indiana from the U.S. apitegromab application while keeping its September 30 FDA decision date intact, but the manufacturing issue has forced a European filing withdrawal and resubmission.
Mitsui’s Kassø e-methanol lands OMV as RFNBO offtaker, unlocking EU land fuel demand
Mitsui and European Energy added OMV as RFNBO offtaker for Kassø's e-methanol; four verticals now anchor a plant whose value lies in template, not tonnage.
Eli Lilly (NYSE: LLY) raises 2026 guidance as Mounjaro and Zepbound reshape pharma growth
Eli Lilly raises 2026 guidance as Mounjaro and Zepbound drive 48% Q2 revenue growth. Read how LLY’s GLP-1 scale reshapes Big Pharma.
Septerna’s oral hypoparathyroidism strategy gets its first human pharmacokinetic validation
SEP-479’s 3-to-4-day half-life supports once-daily dosing as Septerna targets an oral alternative in hypoparathyroidism. See what comes next.
Amgen data breach: Patient records exposed via third-party cloud storage
Amgen said patient health data was exfiltrated via third-party cloud storage in an incident deemed material days before its August 4 Q2 earnings release.
Rhythm Pharmaceuticals (RYTM) TRANSCEND trial in NEJM shows 19.8% placebo-adjusted BMI reduction
Rhythm Pharma (RYTM) TRANSCEND Phase 3 published in NEJM validates IMCIVREE for acquired hypothalamic obesity. 10,000-patient US market launch trajectory ahead.
Vertex (VRTX) to enter endocrine diseases with $10bn Crinetics acquisition, targets $5bn peak revenue by 2029
Vertex Pharmaceuticals to acquire Crinetics for $10 billion at 102% premium, largest deal in VRTX history. Read the full analysis.
Why MedPal AI (AIM: MPAL) is betting on today’s oral Wegovy launch
Oral Wegovy launches in the UK today. MedPal AI just raised ÂŁ5m and bought a care-home tech firm to try to ride the wave from day one.
Medicare GLP-1 Bridge launches July 1: $50/month Wegovy, Foundayo, Zepbound covered
Medicare GLP-1 Bridge starts today at $50/month. Wegovy, Zepbound KwikPen and Foundayo are in; Ozempic and Mounjaro are out. Novo and Lilly split the win.
Eli Lilly (LLY) drug access strategy puts pricing, Medicare and GLP-1 growth in focus
Find out how Eli Lilly’s drug access strategy could reshape LLY stock, GLP-1 pricing, Medicare coverage and pharma competition.